Vnitr Lek 2024, 70(6):384-388 | DOI: 10.36290/vnl.2024.076

Fixed combination of amlodipine and bisoprolol

Jaroslav Brotánek
Interní klinika 3. lékařské fakulty Univerzity Karlovy a Fakultní Thomayerovy nemocnice; 1. lékařská fakulta Univerzity Karlovy

Hypertension is one of the most important cardiovascular risk factors and is closely associated with increased cardiovascular morbidity and mortality. This article discusses the use of fixed combination therapy with amlodipine and bisoprolol in clinical practice. This combination leads to successful achievement of target blood pressure values and also improves patient adherence to treatment. The article also considers suitable indications for which it is preferable to use this drug.

Keywords: hypertension, fixed-dose combination therapy, adherence, amlodipine, bisoprolol.

Accepted: September 19, 2024; Published: October 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brotánek J. Fixed combination of amlodipine and bisoprolol. Vnitr Lek. 2024;70(6):384-388. doi: 10.36290/vnl.2024.076.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze Doporučení České společnosti pro hypertenzi DOPORUČENÉ POSTUPY Diagnostické a léčebné postupy u arteriální hypertenze- verze 2022. Doporučení České společnosti pro hypertenzi. Hypertenze & kardiovaskulární prevence. 2022;12(2)1-25.
    2. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens. 41(12):1874-2071. Go to original source... Go to PubMed...
    3. Wohlfahrt P Časná kompenzace hypertenze aneb jak se nedostat tam, odkud není cesty zpět. Med Praxi. 2022;19(5):385-390.
    4. Suvila K, McCabe EL, Lehtonen A, et al. Early Onset Hypertension Is Associated With Hypertensive End-Organ Damage Already by MidLife. Hypertension. 2019 Jul 1: HYPER TENSIONAHA11913069. Go to original source...
    5. Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle -Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015;131(24):2104-2113. Go to original source... Go to PubMed...
    6. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Medicine. 2009;122(3):290-300. Go to original source... Go to PubMed...
    7. Gradman AH, Parisé H, Lefebvre P, et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61:309-318. Go to original source... Go to PubMed...
    8. Mu L, Mukamal KJ. Treatment Intensification for Hypertension in US Ambulatory Medical Care. J Am Heart Assoc. 2016; e004188. Available from: https://www.ahajournals.org/doi/full/10.1161/JAHA.116.004188. Go to original source... Go to PubMed...
    9. Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158. Go to original source... Go to PubMed...
    10. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010 Feb;55(2):399-407. Go to original source... Go to PubMed...
    11. Amlodipin v terapii kardiovaskulárních onemocnění. Medical Tribune; 2012: Available from: https://www.tribune.cz/archiv/amlodipin-v-terapii-kardiovaskularnich-onemocneni/?articleNavigation=1 & titleVolumeContent=1.
    12. Dahlöf B, Sever PS, Poulter NE, et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:895-906. Go to original source... Go to PubMed...
    13. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006 Mar 7;113(9):1213-1225. Go to original source... Go to PubMed...
    14. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA. 2002;288(23):2981-2997. Go to original source... Go to PubMed...
    15. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med. 2008; 359:2417-2428. Go to original source... Go to PubMed...
    16. Julius S, Kjeldsen SE, Weber M, et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022-2031. Go to original source... Go to PubMed...
    17. Pitt B, Byington RP, Furberg CD, et al. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events. Circulation. 2000;102:1503-1510. Go to original source... Go to PubMed...
    18. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004 10;292(18):2217-2225. Go to original source... Go to PubMed...
    19. Cohn JN, Wilson DJ, Neutel J, et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens. 2009;22:137-144. Go to original source... Go to PubMed...
    20. National Institute for Health and clinical Excelence. Hypertension management of hypertension in adults in primary care [Internet]. NICE/BHS, 2006. Available from: www. nice.org.uk/CG034.
    21. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003. Go to original source... Go to PubMed...
    22. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009;3:CD 001841. Go to original source... Go to PubMed...
    23. Law MH, Morfi a JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J. 2009;338:1665-1683. Go to original source... Go to PubMed...
    24. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; Sep 21;42(36):3599-3726.
    25. McDonagh TA, Metra M, Adamo M et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627-3639. Go to original source... Go to PubMed...
    26. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart.J 2018;39,33:3021-3104. Go to original source... Go to PubMed...
    27. Gillman MW, Kannel WB, Belanger A, et al. Infuence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J. 1993;125:1148-54. Go to original source... Go to PubMed...
    28. Benetos A, Rudnichi A, Tomas F, et al. Influence of heart rate on mortality in a French population. Role of age, gender, and blood pressure. Hypertension 1999;33:44-52. Go to original source... Go to PubMed...
    29. Widimský J. Jaké jsou další indikace beta-blokátorů v klinické praxi? Hypertenze & kardiovaskulární prevence. 2023;1:6-8.
    30. Wai B, Kearney LG, Hare DL, et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012;11:14 Go to original source... Go to PubMed...
    31. Rana R, Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. The Ind Prac.t 2008;61(4):225-234.
    32. Jędrusik P., Placha G., Gaciong Z. AMCOR Trial Investigators. Efficacy and safety of bisoprolol 5 mg plus amlodipine 5 mg in patients with hypertension uncontrolled on monotherapy with 5 mg of amlodipine, a phase III multicenter, randomized, double-blind, placebo-controlled clinical trial - the AMCOR study. Curr Med Res Opin. 2023 Jul;39(7):939-946. Go to original source... Go to PubMed...
    33. Hostalek-Gottwald U, Gaciong Z. A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension. Curr Med Res Opin. 2022 Jul;38(7):1047-1053. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.